国际内分泌代谢杂志
國際內分泌代謝雜誌
국제내분비대사잡지
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2014年
1期
40-42
,共3页
GLP-1受体激动剂%肝功能%脂肪含量%非酒精性脂肪性肝病
GLP-1受體激動劑%肝功能%脂肪含量%非酒精性脂肪性肝病
GLP-1수체격동제%간공능%지방함량%비주정성지방성간병
GLP-1 receptor agonist%Liver function%Fat content%Nonalcoholic fatty Liver disease
胰高血糖素样肽-1(GLP-1)受体激动剂作为治疗糖尿病的新型药物得到广泛应用.近年来的研究显示,此类药物能够通过改善血脂水平、降低脂肪含量、减少肝脂肪变性、肝纤维化程度及细胞死亡等机制,实现降低转氨酶水平以改善非酒精性脂肪性肝病的作用.
胰高血糖素樣肽-1(GLP-1)受體激動劑作為治療糖尿病的新型藥物得到廣汎應用.近年來的研究顯示,此類藥物能夠通過改善血脂水平、降低脂肪含量、減少肝脂肪變性、肝纖維化程度及細胞死亡等機製,實現降低轉氨酶水平以改善非酒精性脂肪性肝病的作用.
이고혈당소양태-1(GLP-1)수체격동제작위치료당뇨병적신형약물득도엄범응용.근년래적연구현시,차류약물능구통과개선혈지수평、강저지방함량、감소간지방변성、간섬유화정도급세포사망등궤제,실현강저전안매수평이개선비주정성지방성간병적작용.
As new antidiabetic drugs,glucagon-like peptide-1 (GLP-1) receptor agonists have been widely used.Recent studies suggest that these drugs can reduce transaminase level to improve nonalcoholic fatty liver disease by improving blood lipid levels,decreasing the content of fat,reducing fatty degeneration of the liver,the degree of liver fibrosis and cell death.
